Thermo Fisher Scientific Collaborates with Janssen to Co-Develop CDx for Multiple Cancer Indications

 Thermo Fisher Scientific Collaborates with Janssen to Co-Develop CDx for Multiple Cancer Indications

Thermo Fisher Scientific Collaborates with Janssen to Co-Develop CDx for Multiple Cancer Indications

Shots:

  • The alliance will validate multiple biomarkers to be used in Thermo Fisher’s Oncomine Dx Target Test, which will be used to identify variant-positive patients for enrollment into clinical studies focusing NSCLC and may follow other cancer indications
  • The ability of the Oncomine Dx Target test to rapidly detect variants from small quantities of DNA/ RNA samples makes it a focus of multiple drug development and clinical trial support agreements, signed b/w Thermo Fisher and other companies
  • Oncomine Dx Target Test is an NGS assay that contains 46 cancer-related biomarkers and a workflow, featuring a fast turnaround time and the lowest sample requirements on the market for the detection of both DNA and RNA variants and has received the US FDA’s approval in 2017

Click here ­to­ read full press release/ article | Ref: Thermo Fisher | Image: Pinterest

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post